AR104829A1 - Derivados de aminoésteres - Google Patents
Derivados de aminoésteresInfo
- Publication number
- AR104829A1 AR104829A1 ARP160101581A ARP160101581A AR104829A1 AR 104829 A1 AR104829 A1 AR 104829A1 AR P160101581 A ARP160101581 A AR P160101581A AR P160101581 A ARP160101581 A AR P160101581A AR 104829 A1 AR104829 A1 AR 104829A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- hydrogen
- cycloalkyl
- diyl
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 14
- 239000001257 hydrogen Substances 0.000 abstract 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 8
- -1 -SO2NR10R11 Chemical group 0.000 abstract 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula general (1), donde cada R¹ es hidrógeno o se selecciona de forma independiente del grupo que consiste en: halógeno, C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, hidroxi, -SO₂NR⁶R⁷, -CN, -NR⁸SO₂R⁹, -NR⁶R⁷, -CONR⁶R⁷ y -NR⁸COR⁹ y donde dicho C₁₋₄ alquilo está opcionalmente sustituido con uno o más grupos seleccionados entre C₃₋₇ cicloalquilo, hidroxi y -NR⁶R⁷ y donde dicho C₁₋₄ alcoxi está opcionalmente sustituido con uno o más halógenos o grupos C₃₋₇ cicloalquilo donde, R⁶ es hidrógeno o C₁₋₆ alquilo; R⁷ es hidrógeno o C₁₋₆ alquilo; R⁸ es hidrógeno o C₁₋₆ alquilo; R⁹ es hidrógeno o C₁₋₆ alquilo; n es un entero entre 1 y 3; cada R² es hidrógeno o se selecciona del grupo que consiste en halógeno, C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, hidroxi, -SO₂NR¹⁰R¹¹, -CN y -NR¹²SO₂R¹⁶ y donde dicho C₁₋₄ alquilo y dicho C₁₋₄ alcoxi se sustituyen opcionalmente con uno o más grupos C₃₋₇ cicloalquilo donde R¹⁰ es hidrógeno o C₁₋₆ alquilo; R¹¹ es hidrógeno o C₁₋₆ alquilo; R¹² es hidrógeno o C₁₋₆ alquilo; R¹³ es hidrógeno o C₁₋₆ alquilo; m es un entero entre 1 y 3; R³ y R⁴ son diferentes o iguales y se seleccionan en forma independiente entre el grupo que consiste en: H, C₃₋₇ cicloalquilcarbonilo, C₁₋₆ alquilo opcionalmente sustituido con uno o más sustituyentes y seleccionados entre C₁₋₄ alcoxi, C₃₋₇ cicloalquilo o C₅₋₇ cicloalquenilo, C₁₋₆ haloalquilo, C₃₋₇ cicloalquilo, C₅₋₇ cicloalquenilo, C₂₋₆ alquenilo, y C₂₋₆ alquinilo; cada R⁵, cuando está presente, se selecciona en forma independiente entre el grupo que consiste en: CN, NO₂, CF₃ y átomos de halógeno; k es 0 o es un entero entre 1 y 3; W¹ se selecciona entre un grupo heteroarileno divalente; W² se selecciona entre un arilo y un heteroarilo o C₃₋₇ cicloalquilo; L es una unión o un grupo -(CH₂)-; L¹ se selecciona entre la lista que consiste de: una unión, -(CH₂)ₚ-, [3]-(CH₂)ₚ-O-[4], [3]-(CH₂)ₚ-NR¹⁰-(CH₂)ₜ-[4], [3]-(CH₂)ₚ-OC(O)-[4], [3]-(CH₂)ₚ-NR¹⁰C(O)-[4], [3]-(CH₂)ₚ-NR¹⁰S(O₂)-[4], y [3]-(CH₂)ₚ-S(O₂)-N(R¹⁰)-[4], donde [3] y [4] representan, respectivamente el punto de unión del grupo L¹ al grupo carbonilo y al anillo W¹ y donde R¹⁰ es como se describe precedentemente, p es un entero entre 1 y 4 y t es un entero entre 1 y 4; L² es un grupo seleccionado entre -(CH₂)q- donde q es un entero entre 1 y 4; L³ es un C₁₋₄ alquileno; X es un grupo seleccionado entre los compuestos de fórmula (2), (3) y (4) donde [1], representan en cada caso el punto de unión del grupo X a L², [2a] el punto de unión a L-W² y [2b] el punto de unión al grupo carbonilo -CO₂A; y donde R¹⁴ se selecciona del grupo que consiste en H, OH, C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, y -CN, donde dicho C₁₋₄ alquilo está opcionalmente sustituido con uno o más grupos seleccionados entre C₃₋₇ cicloalquilo e hidroxilo, o, como alternativa, cuando R¹⁴ es C₁₋₄ alquilo, W² es un anillo fenilo, uno de R¹ es un alquilo en posición orto con respecto a L, ambos R¹ y R¹⁴ pueden estar conectados para formar con W² un radical cíclico condensado entre al menos 1H-ciclopropabencen-1,1-diilo, indan-1,1-diilo (también denominado 2,3-dihidro-1H-inden-1,1-diilo), indan-2,2-diilo (también denominado 2,3-dihidro-1H-inden-2,2-diilo), 1,2,3,4-tetrahidronaftalen-1,1-diilo, y 1,2,3,4-tetrahidronaftalen-2,2-diilo; R¹⁵ se selecciona entre hidrógeno, C₁₋₆ alquilo, C₃₋₇ cicloalquilo, C₃₋₇ heterocicloalquilo y bencilo; donde dicho C₁₋₆ alquilo está opcionalmente sustituido con hidroxilo o NR¹⁸R¹⁹; estando dichos R¹⁸ y R¹⁹ seleccionados en forma independiente entre hidrógeno y C₁₋₄ alquilo, o, tomados junto con el átomo de nitrógeno al estar unidos, forman un nitrógeno que contiene, un grupo heterocicloalquilo saturado, que contiene opcionalmente un heteroátomo adicional seleccionado entre O, S y NH; y donde i es 1 ó 2; i es 1 ó 2, i es un entero entre 0 y 3; A se selecciona entre los grupos de fórmula (i) a (vi) del grupo de fórmulas (5) donde R¹⁶ se selecciona en cada caso en forma independiente entre C₁₋₄ alquilo opcionalmente sustituido con uno o más grupos C₁₋₄ alcoxi; R¹⁷ es hidrógeno, halógeno o C₁₋₄ alquilo; f = 0, 1, 2 ó 3; g = 0, 1, 2 ó 3; y el asterisco (*) representa el punto de unión al grupo L³ en la fórmula (1); sus N-óxidos en el anillo piridina, derivados deuterados, y sales aceptables farmacéuticamente, o solvatos de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15170041 | 2015-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104829A1 true AR104829A1 (es) | 2017-08-16 |
Family
ID=53284074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101581A AR104829A1 (es) | 2015-06-01 | 2016-05-30 | Derivados de aminoésteres |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9636336B2 (es) |
| EP (1) | EP3303328B1 (es) |
| KR (1) | KR20180011123A (es) |
| CN (1) | CN107667103A (es) |
| AR (1) | AR104829A1 (es) |
| BR (1) | BR112017025901A2 (es) |
| CA (1) | CA2987483A1 (es) |
| HK (1) | HK1248237A1 (es) |
| MX (1) | MX2017015300A (es) |
| RU (1) | RU2017141411A (es) |
| TR (1) | TR201908391T4 (es) |
| TW (1) | TW201710254A (es) |
| WO (1) | WO2016193244A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN115466169B (zh) * | 2021-06-10 | 2024-03-26 | 中国医学科学院药物研究所 | 取代邻苯二酚醚类化合物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2022783A1 (en) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| UA111198C2 (uk) * | 2011-06-06 | 2016-04-11 | К'Єзі Фармачеутічі С.П.А. | Похідні 1-феніл-2-піридинілалкільних спиртів як інгібітори фосфодіестерази |
| CN103827088B (zh) * | 2011-09-26 | 2017-10-13 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物 |
| BR112014009471A2 (pt) * | 2011-10-21 | 2017-04-18 | Chiesi Farm Spa | compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit |
| BR112014029642A2 (pt) * | 2012-06-04 | 2017-06-27 | Chiesi Farm Spa | composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit |
| CA2893622A1 (en) | 2012-12-05 | 2014-06-12 | Chiesi Farmaceutici S.P.A. | Novel compounds |
| BR112015012720A2 (pt) | 2012-12-05 | 2017-07-11 | Chiesi Farm Spa | derivados de feniletilpiridina como inibidores de pde4 |
| CN104822669A (zh) * | 2012-12-05 | 2015-08-05 | 奇斯药制品公司 | 作为pde-4抑制剂的苯基乙基吡啶衍生物 |
| WO2014086865A1 (en) * | 2012-12-05 | 2014-06-12 | Chiesi Farmaceutici S.P.A. | 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors |
| RU2016121854A (ru) * | 2013-12-05 | 2017-12-07 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные гетероарила |
| AR098622A1 (es) | 2013-12-05 | 2016-06-01 | Chiesi Farm Spa | Derivados de benzhidrilo |
| US9763924B2 (en) * | 2014-06-05 | 2017-09-19 | Chiesi Farmaceutici S.P.A. | Aminoester derivatives |
-
2016
- 2016-05-30 AR ARP160101581A patent/AR104829A1/es unknown
- 2016-05-30 TW TW105116849A patent/TW201710254A/zh unknown
- 2016-05-31 US US15/168,425 patent/US9636336B2/en active Active
- 2016-05-31 CA CA2987483A patent/CA2987483A1/en not_active Abandoned
- 2016-05-31 BR BR112017025901A patent/BR112017025901A2/pt not_active Application Discontinuation
- 2016-05-31 EP EP16730700.8A patent/EP3303328B1/en active Active
- 2016-05-31 WO PCT/EP2016/062229 patent/WO2016193244A1/en active Application Filing
- 2016-05-31 TR TR2019/08391T patent/TR201908391T4/tr unknown
- 2016-05-31 CN CN201680031970.5A patent/CN107667103A/zh active Pending
- 2016-05-31 KR KR1020177034512A patent/KR20180011123A/ko unknown
- 2016-05-31 RU RU2017141411A patent/RU2017141411A/ru not_active Application Discontinuation
- 2016-05-31 MX MX2017015300A patent/MX2017015300A/es unknown
-
2018
- 2018-06-15 HK HK18107818.5A patent/HK1248237A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017141411A (ru) | 2019-07-16 |
| US20160346268A1 (en) | 2016-12-01 |
| KR20180011123A (ko) | 2018-01-31 |
| WO2016193244A1 (en) | 2016-12-08 |
| BR112017025901A2 (pt) | 2018-08-14 |
| EP3303328B1 (en) | 2019-03-20 |
| TW201710254A (zh) | 2017-03-16 |
| CA2987483A1 (en) | 2016-12-08 |
| HK1248237A1 (zh) | 2018-10-12 |
| CN107667103A (zh) | 2018-02-06 |
| EP3303328A1 (en) | 2018-04-11 |
| TR201908391T4 (tr) | 2019-07-22 |
| US9636336B2 (en) | 2017-05-02 |
| MX2017015300A (es) | 2018-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105104A1 (es) | Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR112682A1 (es) | Compuestos herbicidas | |
| AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR093797A1 (es) | Derivados de feniletilpiridina inhibidores de pde-4 | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR103297A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
| AR093339A1 (es) | Analogos de spliceostatina y metodos para su preparacion | |
| AR096837A1 (es) | Heterociclos tricíclicos como inhibidores de proteínas bet | |
| AR093020A1 (es) | Compuestos antiviricos para el vsr | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| AR095198A1 (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR098621A1 (es) | Derivados de heteroarilo | |
| AR093832A1 (es) | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR088474A1 (es) | Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa | |
| AR100879A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas | |
| AR105991A1 (es) | Heteroarilos sustituidos con pirazolilo y su uso como medicamentos | |
| AR093795A1 (es) | Oxidos de piridinio, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades respiratorias | |
| AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR093798A1 (es) | Compuestos | |
| AR114926A1 (es) | Derivados de azaindol como inhibidores de rho-quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |